However, as activation of these genetically modified cells is dependent on exogenous IL-2, in vivo studies have shown reduced expansion, stability and anti-tumor activity of these CAR-T cells, as they lack interaction with co-stimulatory receptors. Here, IL2 is linked to neoplasm.